News
Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
Videos
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conferences
Conference Coverage Conference Listing
Events
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
More
Resources
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story

Subscribe

  • News
  • Videos
  • Conferences
  • Events
  • Resources
  • Subscribe
  • Blood Cancers
    • MPN
    • MDS
    • Myeloma
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Childhood Cancers
  • Gastrointestinal Cancers
    • Colorectal Cancer
    • Esophageal Cancer
    • Gastrointestinal stromal tumor
    • Liver Cancer
    • Pancreatic Cancer
  • Genitourinary Cancers
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
  • Gynecologic Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head & Neck Cancer
  • Leukemia
    • Acute Myeloid Leukemia
    • CLL
  • Lung Cancer
  • Lymphoma
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • Non-Hodgkin Lymphoma
  • Rare Cancers
    • Neuroendocrine Cancer
  • Sarcoma
  • Skin Cancer/Melanoma
  • Thyroid Cancer
Spotlight -
Blogs|
Breast Cancer Webinar Series|
Cancer Horizons|
Clinical Trial Corner|
Heal®|
Publications|
Videos
Advertisement
|Videos|June 29, 2022

Future Perspectives in Renal Cell Carcinoma (RCC)

Author(s)Thomas Hutson, DO, PharmD

Dr Thomas Hutson comments on the TiNivo-2 trial and discusses upcoming and novel therapies for patients with renal cell carcinoma.

Advertisement

Episodes in this series

EP. 1 Treatment Options for Patients with Renal Cell Carcinoma (RCC)
EP. 1 Treatment Options for Patients with Renal Cell Carcinoma (RCC)
EP. 2 Clinical Implications of the TIVO-3 Trial
EP. 2 Clinical Implications of the TIVO-3 Trial
EP. 3 Tivozanib: Adverse Event Profile and How Toxicities are Managed
EP. 3 Tivozanib: Adverse Event Profile and How Toxicities are Managed
EP. 4 Experience with Tivozanib in the 3rd Line Setting for Patients with RCC
EP. 4 Experience with Tivozanib in the 3rd Line Setting for Patients with RCC
EP. 5 Future Perspectives in Renal Cell Carcinoma (RCC)
Now Playing
EP. 5 Future Perspectives in Renal Cell Carcinoma (RCC)

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Advertisement

Related Content

Advertisement
Image of kidney.

TKIs Take Lead After Immunotherapy in Metastatic Kidney Cancer

ByRyan Scott
November 14th 2025
Generated by Google Gemini

Higher BMI Linked to Better Survival in Localized Kidney Cancer

BySpencer Feldman
November 14th 2025
American Indian and Alaskan Native individuals face some of the highest kidney cancer burdens in the United States: © stock.adobe.com.

Kidney Cancer Disparities Persist Among American Indian and Alaskan Native Patients

ByAlex Biese
November 14th 2025
image of woman.

New Book Spotlights Cancer in Early Adulthood

ByCristina Pozo-Kaderman
November 5th 2025
Image of woman.

Community of Support Available for Patients With Cancer

ByAlyson B. Moadel-Robblee
October 28th 2025
Advertisement
Advertisement

Trending on CURE

1

Breaking Down Advancements in Prostate Cancer Care

2

FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer

3

When One Blood Draw Could Tell More: A Look at the Cancerguard Test

4

Shared Loss Leads to Lifelong Friendship in Rare Cancer Caregiving

5

FDA Grants Drug Designation to Tinostamustine for Malignant Glioma

  • About Us
  • Advertise / Support
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • TargetedOnc.com
  • OncLive.com
  • OncNursingNews.com
  • Terms & Conditions
  • Privacy
  • Do Not Sell My Information
  • Washington My Health My Data
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.